Editorial: Biosimilars – The Center of Attraction of Pharma Industry
Biosimilars, also known as follow-on-biologics are “duplicate” and licensed versions of the biologics that have lost their patent and are produced by some other company. Biosimilars have no clinically meaningful differences from the original or reference product. Moreover, regulations for biosimilar play an important
